Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody1

The experimental autoimmune encephalomyelitis (EAE) model in the common marmoset approximates recognized features of the human disease multiple sclerosis (MS) with regard to its clinical presentation as well as neuropathological and radiological aspects of the lesions in brain and spinal cord. IL-12 is a proinflammatory cytokine that is produced by APC and promotes differentiation of Th1 effector cells. IL-12 is produced in the developing lesions of patients with MS as well as in EAE-affected animals. Previously it was shown that interference in IL-12 pathways effectively prevents EAE in rodents. In this study we report that in vivo neutralization of IL-12p40 using a novel Ab has beneficial effects in the myelin-induced EAE model in common marmosets. The Ab was injected i.v. at 7-day intervals starting well after immunization (day 14) and was continued until the end of the study (day 86). Stable levels of the Ab were measured 3 days after each injection throughout the study period. During this period anti-Ab responses could not be detected. We demonstrate that anti-IL-12p40 treatment has a protective effect on the neurological dysfunction as well as on neuropathological changes normally observed in the brain and spinal cord of EAE-affected individuals.

[1]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[2]  E. Lo,et al.  Drug delivery to damaged brain , 2001, Brain Research Reviews.

[3]  S. Hauser,et al.  Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus , 2001, Immunological reviews.

[4]  R. Bontrop,et al.  Non‐human primate models of multiple sclerosis , 2001, Immunological reviews.

[5]  L. Boon,et al.  Prevention of Experimental Autoimmune Encephalomyelitis in the Common Marmoset (Callithrix jacchus) Using a Chimeric Antagonist Monoclonal Antibody Against Human CD40 Is Associated with Altered B Cell Responses1 , 2001, The Journal of Immunology.

[6]  D. Dunger,et al.  Increased Bone Mineral Density and Serum Leptin in Non-Obese Girls with Precocious Pubarche: Relation to Low Birthweight and Hyperinsulinism , 2001, Hormone Research in Paediatrics.

[7]  J. Leonard,et al.  Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. , 2001, The American journal of pathology.

[8]  P. Villoslada,et al.  Immune Responses Against the Myelin/Oligodendrocyte Glycoprotein in Experimental Autoimmune Demyelination , 2001, Journal of Clinical Immunology.

[9]  B. Boehm,et al.  Frequencies of Neuroantigen-Specific T Cells in the Central Nervous System Versus the Immune Periphery During the Course of Experimental Allergic Encephalomyelitis1 , 2001, The Journal of Immunology.

[10]  C. Du,et al.  Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage, Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice , 2001, Journal of Neuroimmunology.

[11]  L. Roccatagliata,et al.  Demyelination and axonal damage in a non-human primate model of multiple sclerosis , 2001, Journal of the Neurological Sciences.

[12]  J. Antel,et al.  Genetic models for CNS inflammation , 2001, Nature Medicine.

[13]  H. Link,et al.  Monocytes in multiple sclerosis: phenotype and cytokine profile , 2001, Journal of Neuroimmunology.

[14]  V. Tuohy,et al.  Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[15]  C. Polman,et al.  Contrasting responses to interferon β‐1b treatment in relapsing‐remitting multiple sclerosis: Does baseline interleukin‐12p35 messenger RNA predict the efficacy of treatment? , 2000, Annals of neurology.

[16]  M. Glennie,et al.  Clinical trials of antibody therapy. , 2000, Immunology today.

[17]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[18]  Y. Matsumoto,et al.  Characterization of acute versus chronic relapsing autoimmune encephalomyelitis in DA rats , 2000, Journal of Neuroimmunology.

[19]  M. Little,et al.  Of mice and men: hybridoma and recombinant antibodies. , 2000, Immunology today.

[20]  H. Weiner,et al.  Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS , 2000, Neurology.

[21]  K. Nicolay,et al.  Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24–36 Is Presented by a Monomorphic MHC Class II Molecule1 , 2000, The Journal of Immunology.

[22]  Xin Wang,et al.  IFN-β-1b Inhibits IL-12 Production in Peripheral Blood Mononuclear Cells in an IL-10-Dependent Mechanism: Relevance to IFN-β-1b Therapeutic Effects in Multiple Sclerosis1 , 2000, The Journal of Immunology.

[23]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[24]  A. Stalder,et al.  Astrocyte-Targeted Expression of IL-12 Induces Active Cellular Immune Responses in the Central Nervous System and Modulates Experimental Allergic Encephalomyelitis1 , 2000, The Journal of Immunology.

[25]  Jack P Antel,et al.  CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS , 2000, Journal of Neuroimmunology.

[26]  A. Komiyama,et al.  Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing–remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide , 2000, Journal of Neuroimmunology.

[27]  John T. Chang,et al.  Role of Costimulation in the Induction of the IL-12/IL-12 Receptor Pathway and the Development of Autoimmunity , 2000, The Journal of Immunology.

[28]  J. Laman,et al.  Pararosaniline Fixation for Detection of Co-stimulatory Molecules, Cytokines, and Specific Antibody , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  G. Trinchieri,et al.  IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE) , 1999, Journal of the Neurological Sciences.

[30]  S. Hauser,et al.  Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen‐specific antibody mediation , 1999, Annals of neurology.

[31]  J. Frank,et al.  Serial MR imaging of experimental autoimmune encephalomyelitis induced by human white matter or by chimeric myelin-basic and proteolipid protein in the common marmoset. , 1999, AJNR. American journal of neuroradiology.

[32]  F. Barkhof,et al.  Decreased interleukin‐10 and increased interleukin‐12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis , 1999, Annals of neurology.

[33]  R. Voskuhl,et al.  Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis. , 1999, Journal of immunology.

[34]  J. Frank,et al.  Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. , 1999, Journal of immunology.

[35]  N. G. Groot,et al.  Major histocompatibility complex class II polymorphisms in primates , 1999, Immunological reviews.

[36]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[37]  C. Sindic,et al.  B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor-β mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients , 1998, Journal of Neuroimmunology.

[38]  G. Trinchieri,et al.  Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. , 1998, Journal of immunology.

[39]  H. Lassmann,et al.  Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology , 1998, Brain pathology.

[40]  S. Sriram,et al.  Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-1-mediated Th1 differentiation; an effect of the novel anti-inflammatory drug lisofylline , 1998, Journal of Neuroimmunology.

[41]  M. Hennerici,et al.  Increased release of interleukin-12p40 in MS , 1998, Neurology.

[42]  H. Lassmann,et al.  Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). , 1998, The American journal of pathology.

[43]  H. Lassmann,et al.  Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus) , 1998, Journal of Neuroimmunology.

[44]  G. V. van Seventer,et al.  Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. , 1998, Journal of immunology.

[45]  C. Du,et al.  Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis , 1998, Journal of Neuroimmunology.

[46]  S. Miller,et al.  Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading , 1997, Nature Medicine.

[47]  M. Jensen,et al.  Central nervous system cytokine mRNA expression following Theiler's murine encephalomyelitis virus infection , 1997, Journal of Neuroimmunology.

[48]  J. Leonard,et al.  Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. , 1997, The American journal of pathology.

[49]  R. Bontrop,et al.  The common marmoset: A new world primate species with limited Mhc class II variability , 1997 .

[50]  S. Hauser,et al.  Characterization of the TCRB chain repertoire in the New World monkey Callithrix jacchus. , 1997, Journal of immunology.

[51]  G. Trinchieri,et al.  Astrocytes and Microglia Produce Interleukin‐12 p40 a , 1996, Annals of the New York Academy of Sciences.

[52]  V. Fedorowicz,et al.  Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. , 1996, The Journal of clinical investigation.

[53]  E. Shevach,et al.  IL-12 unmasks latent autoimmune disease in resistant mice , 1996, The Journal of experimental medicine.

[54]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[55]  A. Aruffo,et al.  CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Leonard,et al.  Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. , 1996, The American journal of pathology.

[57]  D. Hafler,et al.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.

[58]  T. Olsson,et al.  Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β , 1995, Journal of Neuroimmunology.

[59]  J. Leonard,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 , 1995, The Journal of experimental medicine.

[60]  E. Shevach,et al.  The critical role of IL-12 and the IL-12Rβ2 subunit in the generation of pathogenic autoreactive Th1 cells , 2004, Springer Seminars in Immunopathology.

[61]  G. Trinchieri,et al.  Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively. , 2001, Clinical immunology.

[62]  C. Karp,et al.  Interferon β in multiple sclerosis: is IL-12 suppression the key? , 2000 .

[63]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[64]  L.,et al.  Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4 (cid:49) T cells via CD40 ligand , 1997 .